VanEck Associates’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-4,829
| Closed | -$94K | – | 1319 |
|
|
2021
Q1 | $94K | Buy |
4,829
+71
| +1% | +$1.38K | ﹤0.01% | 1012 |
|
|
2020
Q4 | $86K | Sell |
4,758
-998
| -17% | -$18K | ﹤0.01% | 925 |
|
|
2020
Q3 | $111K | Buy |
5,756
+119
| +2% | +$2.3K | ﹤0.01% | 876 |
|
|
2020
Q2 | $147K | Sell |
5,637
-177
| -3% | -$4.62K | ﹤0.01% | 828 |
|
|
2020
Q1 | $104K | Buy |
5,814
+198
| +4% | +$3.54K | ﹤0.01% | 824 |
|
|
2019
Q4 | $187K | Sell |
5,616
-216
| -4% | -$7.19K | ﹤0.01% | 825 |
|
|
2019
Q3 | $139K | Buy |
5,832
+19
| +0.3% | +$453 | ﹤0.01% | 738 |
|
|
2019
Q2 | $209K | Buy |
5,813
+1,345
| +30% | +$48.4K | ﹤0.01% | 715 |
|
|
2019
Q1 | $165K | Buy |
4,468
+104
| +2% | +$3.84K | ﹤0.01% | 728 |
|
|
2018
Q4 | $188K | Buy |
4,364
+944
| +28% | +$40.7K | ﹤0.01% | 708 |
|
|
2018
Q3 | $162K | Buy |
3,420
+196
| +6% | +$9.28K | ﹤0.01% | 726 |
|
|
2018
Q2 | $160K | Buy |
3,224
+198
| +7% | +$9.83K | ﹤0.01% | 731 |
|
|
2018
Q1 | $150K | Buy |
3,026
+202
| +7% | +$10K | ﹤0.01% | 622 |
|
|
2017
Q4 | $105K | Buy |
+2,824
| New | +$105K | ﹤0.01% | 628 |
|